Reported 1 day ago
Corcept Therapeutics Inc. (NASDAQ:CORT) is gaining momentum as a promising multibagger stock despite a recent reduction in its 2025 revenue guidance to $850-$900 million. The company's CEO expressed confidence in the potential of relacorilant, expecting significant revenue from its commercialization by December 2025. With plans to enhance their pharmacy capacity and an established oncology division, analysts predict a strong outlook for Corcept, which has already seen its stock price double over the past year.
Source: YAHOO